![Yury Kukushkin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yury Kukushkin
Direttore/Membro del Consiglio presso Veralox Therapeutics, Inc.
Posizioni attive di Yury Kukushkin
Società | Posizione | Inizio | Fine |
---|---|---|---|
Veralox Therapeutics, Inc.
![]() Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Direttore/Membro del Consiglio | 01/12/2020 | - |
Code Biotherapeutics, Inc.
![]() Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Direttore/Membro del Consiglio | 01/03/2021 | - |
Hevolution Foundation | Corporate Officer/Principal | 01/09/2023 | - |
Storia della carriera di Yury Kukushkin
Precedenti posizioni note di Yury Kukushkin
Società | Posizione | Inizio | Fine |
---|---|---|---|
4bio Capital Partners | Investitore di Private Equity | 01/05/2016 | 01/09/2023 |
JDRF T1D Fund
![]() JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | Investitore di Private Equity | 01/09/2019 | 01/09/2023 |
Formazione di Yury Kukushkin
Moscow State University Lomonosov | Masters Business Admin |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Max Planck Institute of Biochemistry | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Germania | 3 |
Russia | 2 |
Posizioni
Private Equity Investor | 2 |
Doctorate Degree | 2 |
Director/Board Member | 2 |
Settori
Consumer Services | 4 |
Finance | 3 |
Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 5 |
---|---|
JDRF T1D Fund
![]() JDRF T1D Fund Investment ManagersFinance JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts. | Finance |
4bio Capital Partners | Finance |
Veralox Therapeutics, Inc.
![]() Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD. | Health Technology |
Code Biotherapeutics, Inc.
![]() Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
Hevolution Foundation |
- Borsa valori
- Insiders
- Yury Kukushkin
- Esperienza